Sanofi Wins EU Agency’s Backing for Zaltrap for Cancer

Sanofi and Regeneron Pharmaceuticals Inc. won backing from European Union regulators for their experimental medicine Zaltrap as a second-line treatment for colorectal cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.